- Details
- Ashish Kamat welcomes Hongxian Zhang to present a phase III study comparing blue light cystoscopy (BLC) with white light cystoscopy (WLC) for bladder cancer detection in China. Conducted across seven hospitals from November 2022 to June 2023, the study involved 158 patients, with 114 remaining in the final analysis. It demonstrates that BLC, especially with Hexaminolevulinate (HAL) and modern 4K L...
|
- Details
- Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an oncolytic adenovirus, selectively infects and kills cancer cells while sparing normal tissue and induces antitumor immunity. The phase 3 study showed a 75.7% complete response at any time point, with 7...
|
- Details
- Ashish Kamat welcomes Laura Bukavina to discuss highlights from the SUO 2023 meeting, focusing on bladder cancer research. Dr. Bukavina emphasizes the BOND-003 study on cretostimogene (creto), an adenovirus targeting bladder cancer cells with defective retinoblastoma genes. Creto shows a 75.7% complete response rate, with 74.4% lasting over six months. Another key topic is the ENVISION trial, exam...
|
- Details
- Ruchika Talwar interviews Amanda Myers about her study on at-home intravesical therapy for bladder cancer patients. Dr. Myers' was inspired by patients' desire for a more convenient treatment method. The study, conducted through a cross-sectional survey of the BCAN Patient Survey Network, involved 233 respondents who had undergone at least one dose of intravesical therapy. Key findings include sig...
|
- Details
- Ashish Kamat and Matthew Galsky discuss a phase 2 trial on organ sparing for muscle-invasive bladder cancer, published in Nature Medicine. Dr. Galsky highlights the trial's focus on systemic therapy as an alternative to cystectomy, noting its potential for curative outcomes. The study involved patients receiving gemcitabine-cisplatin plus nivolumab, followed by clinical restaging to identify clini...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trial design in high-risk non-muscle-invasive bladder cancer. The consensus statement, led by Dr. Ashish Kamat and published in the Journal of Clinical Oncology, aims to guide investigators in late-phase clinical trial design. The panel, comprisi...
|
- Details
- Ashish Kamat and Morgan Rouprêt explore advancements in non-muscle-invasive bladder cancer (NMIBC) treatments. Professor Rouprêt emphasizes two NMIBC categories: high-grade disease, where muscle-invasive and high-grade bladder cancer lines blur, and low-grade disease, where de-intensification of follow-up and treatment is sought. He highlights the THOR-2 cohort presented by Jim Catto at ESMO, show...
|
- Details
- Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent, interacting with the heme biosynthetic pathway, causes cancer cells to accumulate photo porphyrins that light up under specific wavelengths. This technology is crucial for patients suspected of having or with a history of bladder cancer, enhan...
|
- Details
- Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic virus targeting cells with retinoblastoma pathway defects, common in cancer cells. This treatment, when instilled in the bladder, prompts immune cells to destroy cancer cells. Highlighted are several key trials: CORE-00...
|
- Details
- Siamak Daneshmand hosts Trinity Bivalacqua to discuss advancements in non-muscle invasive bladder cancer, particularly focusing on newly FDA-approved therapies. Dr. Bivalacqua highlights the excitement surrounding the approval of new treatments for BCG unresponsive bladder cancer, including pembrolizumab and nadofaragene (ADSTILADRIN). He explains the significance of these developments, particular...
|
